Proteinase-activated receptors: Tethered ligands and receptor-activating peptides

被引:5
|
作者
Hollenberg, MD
机构
[1] Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Diabet Endocrine Grp, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Dept Pharmacol & Therapeut, Mucosal Inflammat Grp, Calgary, AB T2N 4N1, Canada
[3] Univ Calgary, Dept Pharmacol & Therapeut, Smooth Muscle & Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada
[4] Univ Calgary, Dept Med, Calgary, AB T2N 4N1, Canada
关键词
proteinases; thrombin PAR- activating peptides; inflammation; nociception; GASTRIC SMOOTH-MUSCLE; THROMBIN RECEPTOR; STRUCTURAL REQUIREMENTS; CROSS-REACTIVITY; (PAR(2))-ACTIVATING PEPTIDES; DIFFERENTIAL ACTIVATION; MOLECULAR-CLONING; DISTINCT; PAR(1); IDENTIFICATION;
D O I
10.1002/ddr.10301
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Proteinase-activated receptors (PARs), newly-discovered members of the G-protein-coupled receptor superfamily, comprising four cloned family members (PARs 1 to 4), are activated by the proteolytic unmasking of a "tethered ligand" sequence situated in the N-terminal extracellular receptor domain. Furthermore, synthetic peptides with sequences based on the revealed tethered ligands can, in the absence of proteolysis, trigger receptor signaling. This report reviews the data supporting the tethered ligand mechanism of receptor activation, outlines the utility of the receptor-activating peptides (so-called PAR-APs) for exploring the potential physiological roles of the PARs, and discusses the potential differences between the activation of the receptors via their tethered ligands as opposed to activation by the soluble peptides having the same amino acid sequences. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:336 / 343
页数:8
相关论文
共 50 条
  • [1] Proteinase-activated receptors and nociceptive pathways
    Vergnolle, N
    DRUG DEVELOPMENT RESEARCH, 2003, 59 (04) : 382 - 385
  • [2] Cofactoring and Dimerization of Proteinase-Activated Receptors
    Lin, Huilan
    Liu, Allen P.
    Smith, Thomas H.
    Trejo, JoAnn
    PHARMACOLOGICAL REVIEWS, 2013, 65 (04) : 1198 - 1213
  • [3] Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease
    Hollenberg, M. D.
    Mihara, K.
    Polley, D.
    Suen, J. Y.
    Han, A.
    Fairlie, D. P.
    Ramachandran, R.
    BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (05) : 1180 - 1194
  • [4] Proteinase-Activated Receptor-1 and Immunomodulatory Effects of a PAR1-Activating Peptide in a Mouse Model of Prostatitis
    Stanton, M. Mark
    Nelson, Lisa K.
    Benediktsson, Hallgrimur
    Hollenberg, Morley D.
    Buret, Andre G.
    Ceri, Howard
    MEDIATORS OF INFLAMMATION, 2013, 2013
  • [5] Proteinase-activated receptors (PARs) and immune function
    Fiorucci, S
    Distrutti, E
    DRUG DEVELOPMENT RESEARCH, 2003, 60 (01) : 65 - 70
  • [6] Proteinase-activated receptors (PARs) and the kidney
    Hollenberg, MD
    Wijesuriya, SJ
    Gui, Y
    Loutzenhiser, R
    DRUG DEVELOPMENT RESEARCH, 2003, 60 (01) : 36 - 42
  • [7] Molecular mechanisms regulating Proteinase-Activated Receptors (PARs)
    Chandrabalan, Arundhasa
    Ramachandran, Rithwik
    FEBS JOURNAL, 2021, 288 (08) : 2697 - 2726
  • [8] Proteinase-activated receptors (PARs) in infection and inflammation in the gut
    Vergnolle, Nathalie
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 40 (6-7) : 1219 - 1227
  • [9] Role of proteinase-activated receptors in cutaneous biology and disease
    Rattenholl, A
    Steinhoff, M
    DRUG DEVELOPMENT RESEARCH, 2003, 59 (04) : 408 - 416
  • [10] Dual endothelium-dependent vascular activities of proteinase-activated receptor-2-activating peptides: evidence for receptor heterogeneity
    Roy, SS
    Saifeddine, M
    Loutzenhiser, R
    Triggle, CR
    Hollenberg, MD
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (07) : 1434 - 1440